Tirumala Reddy

Am I audible?

So my question is around the CDMO business, Pharma Intermediates. So with respect to the concentration risk, so I think currently, majority of the business is coming from very few molecules now. So going forward, how are we going to address this molecule risk or customer risk?

Yes. So -- and my next question is about forward integration. So as we are very well placed on Advanced Intermediates. Is there any plan to move forward to APIs? Or are there any queries from customers for asking API development and manufacturing as well?